<DOC>
	<DOCNO>NCT01881230</DOCNO>
	<brief_summary>The purpose study compare safety efficacy nab-paclitaxel combination either gemcitabine carboplatin combination gemcitabine carboplatin first line treatment female subject triple negative metastatic breast cancer ( TNMBC ) metastatic triple negative breast cancer .</brief_summary>
	<brief_title>Evaluate Risk/Benefit Nab Paclitaxel Combination With Gemcitabine Carboplatin Compared Gemcitabine Carboplatin Triple Negative Metastatic Breast Cancer ( Metastatic Triple Negative Breast Cancer )</brief_title>
	<detailed_description>ABI-007-MBC- 001 Phase 2/3 , multicenter , open-label , randomize , study compare safety efficacy weekly nab-paclitaxel combination gemcitabine carboplatin combination gemcitabine carboplatin first line therapy female subject Estrogen Receptor ( ER ) , Progesterone Receptor ( PgR ) , human epidermal growth factor receptor 2 ( HER2 ) negative ( triple negative ) metastatic breast cancer ( TNMBC ) metastatic triple negative breast cancer . In phase 2 portion study , combination nab-paclitaxel plus gemcitabine nab-paclitaxel plus carboplatin evaluate , comparator arm gemcitabine combine carboplatin use . In phase 3 portion study , select nab-paclitaxel combination treatment compare gemcitabine combine carboplatin evaluate progression free survival , safety tolerability , overall survival , disease control rate duration response woman metastatic triple negative breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion meet : 1 . Female subject , age ≥ 18 year time inform consent sign 2 . Pathologically confirm adenocarcinoma breast 3 . Pathologically confirmed triple negative , source document , define follow 1 . Estrogen Receptor ( ER ) Progesterone Receptor ( PgR ) negative : &lt; 1 % tumor cell nuclei immunoreactive presence evidence sample express ER PgR ( positive intrinsic control ) 2 . Human Epidermal Growth Factor Receptor 2 ( HER2 ) negative per American Society Clinical Oncology College American Pathologists ( ASCO/CAP ) guideline i. Immunohistochemistry ( IHC ) 0 1 Fluorescence In Situ Hybridization ( FISH ) negative ( equivalent negative test ) . Subjects IHC 2 must negative Fluorescence In Situ Hybridization ( FISH ) , , ( equivalent negative test ) . 4 . Subjects prior breast cancer history different phenotype ( ie , ER/PgR/HER2 positive ) must pathologic confirmation triple negative disease least one current sit metastasis 5 . Subjects must receive prior adjuvant neoadjuvant anthracycline therapy ; unless ( ) anthracycline treatment indicated best treatment option subject opinion treat physician ; ( b ) anthracycline treatment remain indicated , opinion treat physician , best treatment option subject 's metastatic disease . . Newly diagnose subject present TNMBC eligible study anthracycline treatment indicate best treatment option subject opinion treat physician . 6 . Subjects measurable metastatic disease , define Response Evaluation Criteria Solid Tumors 1.1 ( RECIST 1.1 ) guideline 7 . Life expectancy ≥ 16 week randomization 8 . No prior cytotoxic chemotherapy metastatic breast cancer . Prior immunotherapy and/or monoclonal antibody therapy acceptable . Prior treatment must discontinue least 30 day prior start study treatment related toxicity must resolve Grade 1 less . 9 . Prior neoadjuvant adjuvant chemotherapy , give , must complete least 6 month randomization relate toxicity resolve , document evidence disease progression per RECIST 1.1 guideline require . . If prior neoadjuvant adjuvant chemotherapy contain taxane , gemcitabine , platinum agent , treatment must complete least 12 month randomization 10 . Prior radiotherapy must complete randomization , full recovery acute radiation side effect . At least one measurable lesion must completely outside radiation portal must unequivocal radiologic clinical exam proof progressive disease within radiation portal , accordance RECIST 1.1 guideline 11 . At least 30 day major surgery randomization , full recovery 12 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 13 . Subject follow blood count screen : Absolute Neutrophil Count ( ANC ) ≥ 1500/mm^2 ; Platelets ≥ 100,000/mm^2 ; Hemoglobin ( Hgb ) ≥ 9 g/dL 14 . Subject follow blood chemistry level screen : Aspartate aminotransferase ( AST ) Serum glutamicoxaloacetic transaminase ( SGOT ) , Alanine Aminotransferase ( ALT ) Serum Glutamic Pyruvate Transaminase ( SGPT ) ≤ 2.5 x upper limit normal range ( ULN ) ; hepatic metastasis present ≤ 5.0 x ULN Total serum bilirubin ≤ ULN ; total bilirubin ≤ 3.0 × ULN direct bilirubin within normal range subject document Gilbert 's Syndrome Creatinine clearance &gt; 60 mL/min ( CockcroftGault ) 15 . Females childbearing potential [ define sexually mature woman ( 1 ) undergone hysterectomy ( surgical removal uterus ) bilateral oophorectomy ( surgical removal ovary ) ( 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) ] must : Demonstrate negative serum pregnancy test result screening ( performed central lab ) confirm local negative urine pregnancy dipstick within 72 hour prior first dose IP ) ; pregnancy test sensitivity least 25 mIU/mL ; Either commit true abstinence* heterosexual contact ( must review monthly basis ) agree use , able comply , two physician approve effective contraception method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) without interruption 28 day longer required local guideline , prior start study drug , study therapy ( include dose interruption ) , 28 day discontinuation study longer require local guideline 16 . Females must abstain breastfeed start randomization , study participation 28 day longer required local guideline , IP discontinuation 17 . Understand voluntarily sign informed consent document prior study related assessments/procedures conduct 18 . Able adhere study visit schedule protocol requirement A subject eligible inclusion study follow criterion apply : 1 . Male subject 2 . Concurrent chemotherapy anti tumor therapy breast cancer . Prior immunotherapy &amp; monoclonal antibody therapy acceptable . 3 . Subjects receive prior cytotoxic chemotherapy incomplete resection locoregional recurrent disease 4 . History , know current evidence brain metastasis , include leptomeningeal involvement . 5 . Subjects bone site metastatic disease 6 . Subjects regional lymph node site metastatic disease 7 . Serious intercurrent medical psychiatric illness , include serious active infection 8 . History class IIIV congestive heart failure myocardial infarction within 6 month randomization 9 . History primary malignancy last 5 year prior randomization . Subjects prior breast cancer history eligible , however , recently obtain biopsy must demonstrate triple negative disease ( source document ) . Subjects prior history situ cancer basal localize squamous cell skin cancer eligible . 10 . Subjects history interstitial lung disease , history slowly progressive dyspnea unproductive cough , sarcoidosis , silicosis , idiopathic pulmonary fibrosis , pulmonary hypersensitivity pneumonitis multiple uncontrolled unstable allergy , opinion investigator , may lead serious complication 11 . Peripheral neuropathy Grade ≥ 2 National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) v4.0 12 . Subjects receive investigational product within previous 4 week prior randomization 13 . Subject currently enrol , enroll different clinical study investigational therapeutic procedure perform investigational therapy administer participate study 14 . Pregnant nursing woman 15 . Subjects prior hypersensitivity nabpaclitaxel , gemcitabine , carboplatin platin , nucleoside analogue agent 16 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study 17 . Any condition include presence laboratory abnormality , place subject unacceptable risk participate study 18 . Any condition confound ability interpret data study 19 . History seropositive human immunodeficiency virus ( HIV ) 20 . Subjects receive immunosuppressive myelosuppressive medication would , opinion investigator , increase risk serious neutropenic complication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Cancer Breast</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Metastatic Triple Negative Breast Cancer</keyword>
	<keyword>Triple Negative Breast Cancer</keyword>
	<keyword>Triple Negative Metastatic Breast Cancer</keyword>
	<keyword>Basal-like breast cancer</keyword>
	<keyword>Hormone receptor negative breast cancer</keyword>
	<keyword>Estrogen receptor negative breast cancer</keyword>
	<keyword>Progesterone negative receptor breast cancer</keyword>
	<keyword>HER2 Negative Breast Cancer</keyword>
	<keyword>Abraxane</keyword>
	<keyword>nab-Paclitaxel</keyword>
	<keyword>ABI-007</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>Gemzar</keyword>
	<keyword>carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Paraplatin AQ</keyword>
	<keyword>Phase 2</keyword>
	<keyword>Phase 3</keyword>
</DOC>